Editorial Commentary
Combination metronomic chemotherapy and immunotherapy in non-small cell lung cancer remains exploratory: the VinMetAtezo trial
AME Clinical Trials Review
2024;
2:
12
(25 April 2024)
Editorial Commentary
Immunotherapy as first-line treatment in locally advanced/metastatic and previously untreated squamous cell lung cancer: which advances?
AME Clinical Trials Review
2024;
2:
11
(25 April 2024)
Editorial Commentary
Combining neoadjuvant and adjuvant immunotherapy breathes more life into the growing body of lung cancer treatment paradigms
AME Clinical Trials Review
2024;
2:
10
(25 February 2024)
Editorial Commentary
The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC
AME Clinical Trials Review
2024;
2:
9
(25 February 2024)
Editorial Commentary
Commentary: is segmentectomy curative in patients with early-stage ground glass opacity predominant non-small cell lung cancer?
AME Clinical Trials Review
2024;
2:
8
(25 February 2024)
Editorial Commentary
Changing the way we treat KRAS G12C non-small cell lung cancers
AME Clinical Trials Review
2024;
2:
7
(25 February 2024)
Editorial Commentary
How should we combine radiotherapy and immunotherapy in advanced non-small cell lung cancer?
AME Clinical Trials Review
2024;
2:
6
(25 February 2024)
Editorial Commentary
The role of confirmatory mediastinoscopy after negative endosonography: is it truly necessary?
AME Clinical Trials Review
2024;
2:
5
(25 February 2024)
Editorial Commentary
A long-awaited novel approach for the treatment of undetectable small-sized lung cancers in thoracoscopic surgery
AME Clinical Trials Review
2024;
2:
4
(25 February 2024)
Editorial Commentary
Real-world evidence for immune checkpoint inhibitors in extensive-stage small cell lung cancer
AME Clinical Trials Review
2024;
2:
3
(25 February 2024)
Editorial Commentary
CheckMate 817: expanding the pool of patients eligible for immune checkpoint inhibitor therapy in advanced non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
2
(25 February 2024)
Editorial Commentary
Should we change strategy for adjuvant therapy according to surgery type in stage II–IIIA non-small cell lung cancer?
AME Clinical Trials Review
2024;
2:
1
(25 February 2024)
Editorial Commentary
Two-year analysis of CodeBreaK 100 phase I/II trial: achieved goals of an ongoing challenge
AME Clinical Trials Review
2023;
1:
20
(25 December 2023)
Editorial Commentary
What is the most optimal postoperative chest tube placement method after lung resection?
AME Clinical Trials Review
2023;
1:
19
(25 December 2023)
Editorial Commentary
Tunnel vision: seeking to reduce peritubular leakage after lung resection
AME Clinical Trials Review
2023;
1:
18
(25 December 2023)
Editorial Commentary
The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer
AME Clinical Trials Review
2023;
1:
17
(25 December 2023)
Editorial Commentary
EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges
AME Clinical Trials Review
2023;
1:
16
(25 December 2023)
Editorial Commentary
Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial
AME Clinical Trials Review
2023;
1:
15
(25 December 2023)
Editorial Commentary
The importance of long-term safety, tolerability, and health-related quality of life: lessons from the ADAURA trial
AME Clinical Trials Review
2023;
1:
14
(25 December 2023)
Editorial Commentary
Pafolacianine for imaging of pulmonary neoplasms: a promising supplement for modern surgical technique
AME Clinical Trials Review
2023;
1:
13
(25 December 2023)
Editorial Commentary
Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer
AME Clinical Trials Review
2023;
1:
12
(25 December 2023)
Editorial
A tale of two lung-sparing surgeries: the rise of segmentectomy and wedge resection in stage IA non-small-cell lung cancer
AME Clinical Trials Review
2023;
1:
11
(25 December 2023)
Editorial Commentary
Overall survival of ADAURA: game, set, and match?
AME Clinical Trials Review
2023;
1:
10
(25 October 2023)
Editorial Commentary
What is the role of consolidation immunotherapy after chemoradiotherapy in stage III EGFR-mutant non-small cell lung cancer?
AME Clinical Trials Review
2023;
1:
9
(25 October 2023)
Editorial Commentary
Segmentectomy for partially solid non-small cell lung cancer: what counts—the resection or the patient?
AME Clinical Trials Review
2023;
1:
8
(25 October 2023)
Editorial Commentary
Real world data are needed to establish safety of adjuvant immune checkpoint inhibitors after pneumonectomy
AME Clinical Trials Review
2023;
1:
7
(25 October 2023)
Editorial Commentary
Neoadjuvant immunotherapy for resectable non-small cell lung cancer—what lies ahead
AME Clinical Trials Review
2023;
1:
6
(25 October 2023)
Editorial Commentary
Towards better outcomes: segmentectomy for ground-glass opacity-dominant non-small cell lung cancer 3 cm or less—insights from JCOG1211
AME Clinical Trials Review
2023;
1:
5
(25 October 2023)
Editorial Commentary
The immune “tsunami” has arrived at the shores of early-stage non-small cell lung cancer
AME Clinical Trials Review
2023;
1:
4
(25 October 2023)
Editorial Commentary
An ever-stronger case for circulating tumor DNA monitoring in ALK+ lung cancer
AME Clinical Trials Review
2023;
1:
3
(25 October 2023)